Aimee Donnellan

The arrest of Pavel Durov, founder of the controversial messaging app, and the ban of X in Brazil shows state officials are not afraid to intervene in Big Tech. In this Viewsroom podcast, Breakingviews columnists debate what it means and how CEOs should manage the threat.

UniCredit, the $68 bln Italian lender, grabbed a 9% stake in Germany’s $16 bln Commerzbank. In this Viewsroom podcast, Breakingviews columnists argue that a full merger makes financial sense, but potentially not for unions or the under-fire government in Berlin.

Military escalation between Iran and Israel may at some point affect the price of oil. In this Viewsroom podcast, Breakingviews columnists debate how the conflict may prompt a fresh inflationary headache for central banks – and how Saudi Arabia might offset that risk.

Follow on Apple or Spotify. Listen on the Reuters app. Read the episode transcript.

Follow on Apple or Spotify. Listen on the Reuters app. Read the episode transcript.

Follow on Apple or Spotify. Listen on the Reuters app. Read the episode transcript.

With $31 bln of debt, deep links to the banking system and a star role in India’s energy transition, the tycoon’s empire is a crucial part of the fifth-largest economy. In this week’s Viewsroom, Breakingviews columnists discuss how US bribery charges will test those dependencies.

Follow on Apple or Spotify. Listen on the Reuters app. Read the episode transcript.

Pascal Soriot is stuck in a Chinese limbo. In recent months, the CEO of $205 billion drug giant AstraZeneca has seen his China boss detained by Beijing and his shares underperform rivals. Yet the value which investors assign to his Middle Kingdom operations complicates a quick fix.

Eli Lilly and Novo Nordisk will kick off a massive shopping spree in 2025. The two obesity giants will be sitting on cash piles of around $80 billion by 2028, according to LSEG data, thanks to the runaway success of their weight-loss drugs. The challenge will be to put that money to work and avoid overpaying.